Benchmark has secured an exclusive worldwide license from Saiba Animal Health GmbH, to develop and commercialise a recombinant vaccine for Canine Atopic Dermatitis (CAD) using Virus Like-Particle (VLP) technology. Link to full release from BenchmarkRead More
Archive: November 23, 2015
- Saiba Animal Health AG enters into an Agreement with Boehringer Ingelheim
- Saiba Animal Health led consortium receives top ranking and funding from Eurostars Program for the research and development of a vaccine for African Swine Fever.
- Saiba Animal Health Enters Into an Agreement with a Major Animal Health Company
- Key preclinical data for Saiba Animal Health’s cat allergy vaccine (HypoCat™ / VC001) published in leading allergy journal.
- Saiba Animal Health AG today announced the publication of proof of principle data for a vaccine with the potential to translate into a novel therapy for osteoarthritic pain in companion animals